Amgen, AstraZeneca new asthma drug gets positive phase three results

(Alliance News) - Amgen Inc on Sunday said an asthma drug it's developing with AstraZeneca PLC ...

Alliance News 6 September, 2021 | 6:22AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Amgen Inc on Sunday said an asthma drug it's developing with AstraZeneca PLC was shown to be effective in a phase three trial.

Tezepelumab reduced exacerbations by 86% in patients with severe asthma and comorbid nasal polyps, as well as improving lung function and nasal symptoms, in the Navigator trial.

"These results further strengthen our confidence in tezepelumab's potential to address a significant unmet need across a broad population of patients with severe asthma, including those with comorbid nasal polyps. We look forward to bringing this potentially transformative treatment to patients soon," Amgen Vice President of Research and Development David Reese said.

The Thousand Oaks, California-based pharmaceutical firm added that there are 2.5 million patients with severe asthma who are uncontrolled or eligible for biologic treatment, 1 million of them in the US.

Shares in Amgen closed 0.2% higher at USD226.37 on Friday in New York.

By Ivan Edwards; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 8,699.00 GBX -1.09
Amgen Inc 203.13 USD -2.27

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.